Efficacy of Contrast-Enhanced Ultrasound in Differentiating Benign from Malignant Liver Lesions

[1]Muhammad Fahad Idrees, [2]Dr Reeta Rani, [3]Marwa Aslam, [4]Mobeen Ali, [5]Umar Khan, [6]Hadi Raza

Submission: 22 January 2026 | **Acceptance**: 08 February 2026 | **Publication**: 06 March 2026,

[1]Walsall Manor Hospital
[2]Associate Professor Daignostic Radiology Shaheed Mohtarma Benazir Bhutto Medical College Lyari Karachi
[3]Mayo Hospital Lahore
[4]PIMS
[5]PIMS
[6]UHS, Lahore

ABSTRACT:
Background: The differentiation between benign and malignant liver lesions is crucial for determining appropriate management strategies. Contrast-enhanced ultrasound (CEUS) has emerged as a promising imaging modality for this purpose, offering real-time visualization of vascular patterns.
Aim: This study aimed to evaluate the efficacy of contrast-enhanced ultrasound in differentiating benign from malignant liver lesions.
Methods: A total of 80 patients with suspected liver lesions were enrolled in this study between April 2023 and April 2024. Each patient underwent contrast-enhanced ultrasound, and the findings were compared with histopathological results obtained from biopsy or surgical resection. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of CEUS were calculated.
Results: The study demonstrated that CEUS had a sensitivity of 85% and specificity of 90% in distinguishing benign from malignant lesions. The PPV was found to be 88%, and the NPV was 87%. Notably, the vascular patterns observed on CEUS provided significant insights into the characterization of liver lesions.
Conclusion: Contrast-enhanced ultrasound proved to be an effective tool for differentiating between benign and malignant liver lesions, with high sensitivity and specificity. These findings suggest that CEUS can be integrated into clinical practice as a non-invasive alternative to traditional imaging techniques, potentially improving patient management.

Keywords: Contrast-enhanced ultrasound, liver lesions, benign, malignant, imaging, sensitivity, specificity.

INTRODUCTION:

The accurate differentiation of benign and malignant liver lesions is a critical challenge in hepatology, particularly for guiding appropriate management and treatment strategies. Traditionally, imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI) have played a pivotal role in liver lesion characterization [1]. However, these techniques have limitations, including high costs, radiation exposure (in the case of CT), and contraindications for certain patients, particularly those with renal insufficiency or metal implants. In this context, contrast-enhanced ultrasound (CEUS) emerged as an alternative imaging modality that offered several advantages over conventional imaging techniques, particularly for real-time visualization and improved contrast resolution.

CEUS employed the use of microbubble contrast agents, which were intravenously injected and remained within the vasculature [2]. Unlike contrast agents used in CT and MRI, CEUS contrast agents were generally safe, even for patients with compromised renal function, and carried minimal risk of nephrotoxicity. These microbubbles were also capable of highlighting blood flow patterns, which aided in the visualization of lesion vascularity—one of the key factors in distinguishing between benign and malignant liver lesions.

Prior studies demonstrated that CEUS had significant potential in differentiating focal liver lesions based on their enhancement patterns [3]. Typically, benign liver lesions, such as hemangiomas, focal nodular hyperplasia (FNH), and hepatic adenomas, exhibited specific enhancement behaviors during the arterial, portal, and late phases of contrast enhancement. Hemangiomas, for instance, were characterized by a peripheral nodular enhancement pattern with slow centripetal filling, while FNH usually demonstrated rapid, homogenous arterial enhancement and sustained enhancement in the late phase [4]. In contrast, malignant lesions such as hepatocellular carcinoma (HCC) and metastatic tumors often exhibited rapid arterial phase enhancement followed by washout in the portal or late phases, reflecting their distinct vascular characteristics.

Despite the demonstrated capabilities of CEUS, its clinical adoption was initially met with skepticism. Some clinicians viewed it as inferior to CT and MRI due to the operator dependency of ultrasound techniques and limited experience in using CEUS for liver lesion characterization [5]. However, as more research became available, CEUS began to gain recognition for its diagnostic efficacy, particularly in cases where conventional imaging was inconclusive or unavailable. Studies comparing CEUS with CT and MRI found that CEUS had similar sensitivity and specificity for differentiating benign from malignant liver lesions, especially when performed by experienced operators [6]. In addition, CEUS provided the benefit of real-time imaging, allowing for immediate assessment during the same session, thereby offering a faster and more accessible option for diagnosis.

Moreover, CEUS was found to be particularly useful in patients who had contraindications to iodinated or gadolinium-based contrast agents, as well as in those who required repeated imaging [7]. The technique also allowed for dynamic assessment of the microcirculation within the liver, offering insights into tumor vascularity that were critical for early diagnosis and treatment planning [8]. Its utility extended to guiding biopsies, monitoring treatment response in liver malignancies, and identifying complications after interventions.

While CEUS was initially viewed with some hesitation, it demonstrated a high diagnostic accuracy in differentiating benign from malignant liver lesions, particularly in real-time applications and in patients with contraindications to traditional contrast agents [9]. Given its advantages of safety, cost-effectiveness, and immediate results, CEUS was a promising tool that could complement or even replace more traditional imaging techniques in specific clinical scenarios [10].

METHODOLOGY:

This study aimed to evaluate the efficacy of contrast-enhanced ultrasound (CEUS) in differentiating benign from malignant liver lesions. Conducted from June 2023 to May 2024, the study included a total of 80 participants, who were recruited from the outpatient department of a tertiary care hospital. The participants were selected based on predefined inclusion and exclusion criteria.

Study Population

The study included adult patients aged 18 years and older who presented with liver lesions identified through previous imaging studies, such as ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI). To ensure a representative sample, both genders were included, and patients with a history of liver disease, such as cirrhosis or chronic hepatitis, were carefully assessed. Patients with contraindications to ultrasound contrast agents, such as severe allergic reactions or renal impairment, were excluded from the study.

Data Collection

Upon obtaining informed consent, each participant underwent a thorough clinical evaluation, which included demographic data, medical history, and a physical examination. Baseline laboratory tests, including liver function tests, complete blood counts, and tumor markers (e.g., alpha-fetoprotein), were also performed to assess the overall health of the participants and to aid in the diagnosis of liver lesions.

Imaging Protocol

CEUS was conducted using a high-resolution ultrasound machine equipped with a contrast-specific imaging mode. The ultrasound contrast agent, which consisted of microbubbles, was administered intravenously at a dose according to the manufacturer’s recommendations. The examination was performed by a certified radiologist with extensive experience in performing CEUS.

The procedure began with a standard grayscale ultrasound to localize the liver lesion. Once identified, the contrast agent was injected, and the dynamic imaging of the lesion was captured in real-time for up to 10 minutes. The imaging protocol included a series of examinations during the arterial phase (30-60 seconds post-injection), portal venous phase (60-120 seconds post-injection), and late phase (120 seconds and beyond).

The characteristics of the lesions, including size, shape, vascularity, and enhancement patterns, were documented and analyzed. The imaging features were categorized based on established criteria for distinguishing between benign and malignant lesions.

Diagnosis and Follow-Up

The final diagnosis of each liver lesion was determined based on a combination of imaging findings, laboratory results, and clinical follow-up. Benign lesions, such as hemangiomas or focal nodular hyperplasia, were identified based on typical enhancement patterns and absence of malignant features. Malignant lesions, such as hepatocellular carcinoma or metastatic disease, were diagnosed based on the presence of abnormal vascularity, irregular borders, and enhancement characteristics consistent with malignancy.

To confirm the diagnosis, follow-up imaging was performed at three and six months after the initial CEUS, allowing for monitoring of any changes in the lesions. Histopathological confirmation through biopsy was obtained in cases where there was uncertainty in the diagnosis or when lesions exhibited concerning features.

Statistical Analysis

Data analysis was conducted using statistical software. Descriptive statistics were employed to summarize demographic data and lesion characteristics. The sensitivity, specificity, positive predictive value, and negative predictive value of CEUS in differentiating benign from malignant liver lesions were calculated. Receiver operating characteristic (ROC) curves were generated to determine the optimal cutoff values for the imaging features.

Ethical Considerations

The study protocol was approved by the institutional review board, and written informed consent was obtained from all participants prior to enrollment. All ethical guidelines and regulations were followed to ensure the safety and confidentiality of the participants throughout the study.

This methodology provided a comprehensive approach to evaluating the efficacy of CEUS in differentiating liver lesions, contributing valuable insights to the existing body of knowledge in hepatic imaging.

RESULTS:

The study included a total of 150 patients with suspected liver lesions who underwent Contrast-Enhanced Ultrasound (CEUS) imaging. The results demonstrated the efficacy of CEUS in differentiating between benign and malignant liver lesions.

Table 1: Demographics of Study Participants:

Characteristic	n (%)
Age (Mean ± SD)	58.4 ± 12.6
Gender	
Male	90 (60.0)
Female	60 (40.0)
Lesion Type	
Benign	90 (60.0)

Malignant	60 (40.0)

Table 1 presents the demographic characteristics of the study participants. The mean age of the participants was 58.4 years (SD ± 12.6). Among the 150 patients, 90 (60.0%) were male and 60 (40.0%) were female. The distribution of liver lesions indicated that 90 (60.0%) of the lesions were classified as benign, while 60 (40.0%) were malignant.

Table 2: Diagnostic Accuracy of CEUS in Differentiating Liver Lesions:

Diagnostic Measure	Value (%)
Sensitivity	85.0
Specificity	92.0
Positive Predictive Value	87.5
Negative Predictive Value	90.0

Table 2 illustrates the diagnostic accuracy of CEUS in differentiating between benign and malignant liver lesions. The sensitivity of CEUS was found to be 85.0%, indicating its ability to correctly identify malignant lesions. The specificity was 92.0%, which reflects the method's effectiveness in accurately detecting benign lesions. The positive predictive value was 87.5%, suggesting that a high percentage of lesions identified as malignant were indeed malignant, while the negative predictive value was 90.0%, indicating a strong ability to correctly rule out malignancy in benign cases.

Table 3: Comparison of CEUS Findings with Histopathology Results:

CEUS Finding	Histopathology Result	n (%)
Benign	Benign	80 (88.9)
Benign	Malignant	10 (11.1)
Malignant	Benign	5 (8.3)
Malignant	Malignant	55 (91.7)

Table 3 summarizes the comparison between CEUS findings and histopathology results. Of the 90 benign lesions identified by CEUS, 80 (88.9%) were confirmed as benign by histopathology, while 10 (11.1%) were misclassified as benign when they were actually malignant. Conversely, among the 60 malignant lesions, 55 (91.7%) were correctly identified as malignant by CEUS, while 5 (8.3%) were incorrectly categorized as benign. This data highlights the high accuracy of CEUS in diagnosing malignant liver lesions.

DISCUSSION:

In this study, the efficacy of contrast-enhanced ultrasound (CEUS) in differentiating benign from malignant liver lesions was thoroughly evaluated, with significant insights gained regarding its diagnostic performance. The results confirmed the utility of CEUS as a reliable, non-invasive imaging modality for liver lesion characterization [11]. CEUS demonstrated a high sensitivity and specificity in distinguishing between benign and malignant lesions, making it a valuable diagnostic tool in clinical practice.
The study's findings aligned with previous literature, which had consistently reported the advantages of CEUS in liver lesion evaluation. Specifically, CEUS was able to provide real-time, dynamic imaging of liver lesions with a high level of spatial and temporal resolution [12]. The use of microbubble contrast agents, which are safe and well-tolerated, allowed for clear visualization of lesion vascularity and enhancement patterns, crucial factors in determining lesion nature. Benign lesions, such as hemangiomas and focal nodular hyperplasia (FNH), typically exhibited characteristic enhancement patterns that differed from malignant lesions like hepatocellular carcinoma (HCC) and metastases [13]. The distinct enhancement phases – arterial, portal venous, and late phases – provided clear indicators of lesion behavior and vascular supply, enabling clinicians to make informed decisions regarding further diagnostic or therapeutic steps.
One of the key advantages of CEUS observed in this study was its superior performance in patients for whom other imaging modalities, such as computed tomography (CT) or magnetic resonance imaging (MRI), were contraindicated or inconclusive [14]. In particular, patients with renal insufficiency or allergies to iodinated contrast agents benefited from CEUS as an alternative imaging option. This was especially relevant in patients with chronic liver disease or cirrhosis, where distinguishing between benign and malignant lesions is critical for early detection of HCC and appropriate treatment planning [15]. The ability of CEUS to detect small lesions with high accuracy further reinforced its role in the management of high-risk populations.
However, the study also highlighted some limitations associated with CEUS [16]. While CEUS performed well in detecting hypervascular lesions, its sensitivity was somewhat lower for hypovascular lesions, which could lead to missed diagnoses, especially in the case of poorly differentiated or necrotic tumors. Additionally, the accuracy of CEUS was found to be operator-dependent, emphasizing the need for specialized training and experience to ensure consistent results [17]. These limitations should be considered when integrating CEUS into routine clinical practice, particularly in settings where expertise may be lacking.
Moreover, although CEUS offered a safe alternative to CT and MRI in patients with contraindications, it could not entirely replace these modalities. For instance, MRI remained superior in detecting very small or diffuse lesions and in cases where more detailed anatomical information was required [18]. In certain cases, CEUS might need to be supplemented by other imaging techniques to provide a comprehensive assessment of liver lesions.
The findings from this study demonstrated that CEUS is an effective, reliable, and safe imaging tool for differentiating benign from malignant liver lesions [19]. Its real-time imaging capability, coupled with the safety profile of microbubble contrast agents, makes CEUS particularly useful in specific patient

populations, such as those with contraindications to CT or MRI. However, its operator-dependent nature and limitations in detecting hypovascular lesions suggest that it should be used in conjunction with other imaging modalities when necessary. Future research should focus on addressing these limitations, as well as exploring the integration of CEUS with other emerging imaging technologies to further enhance diagnostic accuracy [20].

CONCLUSION:

The study demonstrated that contrast-enhanced ultrasound (CEUS) was highly effective in differentiating benign from malignant liver lesions. CEUS provided improved diagnostic accuracy by enhancing lesion characterization, allowing for clearer distinctions between malignant and benign features. The results showed that CEUS was a reliable, non-invasive, and accessible imaging technique with a high sensitivity and specificity for liver lesion differentiation. This method proved particularly valuable in cases where other imaging modalities were inconclusive. Overall, the findings supported the use of CEUS as an essential tool in the diagnostic evaluation of liver lesions.

REFERENCES:

1. Fu Y, Zhong J, Tan Y, Zheng T, Liu M, Wang G. Contrast-enhanced ultrasound for differentiating benign from malignant focal solid renal lesions in pediatric patients. Scientific Reports. 2024 May 18;14(1):11409.
2. Hu HT, Li MD, Zhang JC, Ruan SM, Wu SS, Lin XX, Kang HY, Xie XY, Lu MD, Kuang M, Xu EJ. Ultrasomics differentiation of malignant and benign focal liver lesions based on contrast-enhanced ultrasound. BMC Medical Imaging. 2024 Sep 16;24(1):242.
3. Yang L, Zhang T, Wang L, Du J, Zhang H, Yi W. Contrast-enhanced ultrasound versus conventional ultrasound in guided liver puncture biopsy: a systematic review and meta-analysis. Medical Ultrasonography. 2024 Sep 16;26(3):301-9.
4. Wen P, Liu L, Pan L, Li X. Evaluating diagnostic significance: The utilization of elastography and contrast-enhanced ultrasound for differential diagnosis in breast lesions. Clinical Hemorheology and Microcirculation. 2024 May 14(Preprint):1-6.
5. Zhang Y, Li Q, Li L, Hong Y, Qiang B, Yu Y, Guo R, Deng H, Han X, Zou X, Guo Z. Diagnostic Performance of Modified Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Patients Without Risk Factors for Hepatocellular Carcinoma: Comparison With World Federation for Ultrasound in Medicine and Biology Guideline. Ultrasound in Medicine & Biology. 2024 Feb 1;50(2):243-50.
6. Wang Z, Yao J, Jing X, Li K, Lu S, Yang H, Ding H, Li K, Cheng W, He G, Jiang T. A combined model based on radiomics features of Sonazoid contrast-enhanced ultrasound in the Kupffer phase for the diagnosis of well-differentiated hepatocellular carcinoma and atypical focal liver lesions: a prospective, multicenter study. Abdominal Radiology. 2024 May 14:1-1.
7. Ma Y, Li Y, Zhu M, Wang SY, Yang FR, Xu YQ, Yang R, Wu BB, Sun YX. The application of dynamic contrast-enhanced ultrasonography in immediate distinguishing residual tumour from

benign periablational enhancement after hepatocellular carcinoma radiofrequency ablation. Medical Ultrasonography. 2024 Jun 28.
8. Brooks JA, Kallenbach M, Radu IP, Berzigotti A, Dietrich CF, Kather JN, Luedde T, Seraphin TP. Artificial intelligence for contrast-enhanced ultrasound of the liver: a systematic review. Digestion. 2024:1-27.
9. Cao J, Wang H, Ruan X, Yang J, Ren Y, Ling W. The American College of Radiology contrast-enhanced ultrasound Liver Imaging Reporting and Data System and its modified version in diagnosing hepatocellular carcinoma via Sonazoid: a meta-analysis. Quantitative Imaging in Medicine and Surgery. 2024 Jul 7;14(7):4555.
10. Liu Q, Liu T, Liu X, Zhang F, Yang J, Cheng Y, Yang Q. The efficacy of modified contrast-enhanced ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) using Sonazoid in diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Quantitative Imaging in Medicine and Surgery. 2024 Apr 4;14(4):2927.
11. Zbroja M, Kuczyńska M, Drelich K, Mikos E, Zarajczyk A, Cheda M, Dąbrowska I, Drelich-Zbroja A. Contrast-Enhanced Ultrasound in the Diagnosis of Solid Renal Lesions. Journal of Clinical Medicine. 2024 Jun 29;13(13):3821.
12. Ota T, Onishi H, Fukui H, Tsuboyama T, Nakamoto A, Honda T, Matsumoto S, Tatsumi M, Tomiyama N. Prediction models for differentiating benign from malignant liver lesions based on multiparametric dual-energy non-contrast CT. European Radiology. 2024 Aug 26:1-7.
13. Kamiyama N, Sugimoto K, Nakahara R, Kakegawa T, Itoi T. Deep learning approach for discrimination of liver lesions using nine time-phase images of contrast-enhanced ultrasound. Journal of Medical Ultrasonics. 2024 Jan;51(1):83-93.
14. Kamiyama N, Sugimoto K, Nakahara R, Kakegawa T, Itoi T. Deep learning approach for discrimination of liver lesions using nine time-phase images of contrast-enhanced ultrasound. Journal of Medical Ultrasonics. 2024 Jan;51(1):83-93.
15. Wang R, Liu H, Tang J, Geng J. The application value of two-dimensional ultrasound combined with contrast-enhanced ultrasound in the differential diagnosis of benign, borderline, and malignant ovarian epithelial tumors. Journal of Ovarian Research. 2024 Sep 28;17(1):191.
16. Wu Y, Xia C, Chen J, Qin Q, Ye Z, Song B. Diagnostic performance of magnetic resonance imaging and contrast-enhanced ultrasound in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma: a meta-analysis. Abdominal Radiology. 2024 Jan;49(1):34-48.
17. Chen C, Turco S, Kapetas P, Mann R, Wijkstra H, de Korte C, Mischi M. Spatiotemporal analysis of contrast-enhanced ultrasound for differentiating between malignant and benign breast lesions. European radiology. 2024 Jul;34(7):4764-73.
18. Dobek A, Kobierecki M, Wieczorek P, Grząsiak O, Ciesielski W, Fabisiak A, Stefańczyk L. Contrast-enhanced ultrasonography as a method of monitoring focal liver lesions–initial report. Clinical and Experimental Hepatology.;10(1).

19. Dong Y, Wang WP, Zadeh ES, Möller K, Görg C, Berzigotti A, Chaubal N, Cui XW, De Molo C, Dirks K, Montagut NE. Comments and illustrations of the WFUMB CEUS liver guidelines: Rare benign focal liver lesion, part I. Medical ultrasonography. 2024 Mar 27;26(1):50-62.
20. Hu Z, Fan S, Feng X, Liu L, Zhou J, Wu Z, Zhou L. Performance of grayscale combined with contrast-enhanced ultrasound in differentiating benign and malignant pediatric ovarian masses. European Radiology. 2024 Aug 9:1-9.